Mitochon Pharmaceuticals Receives $1 Million ALS Association Award to Advance MP-101 Clinical Development
Mitochon Pharmaceuticals has announced that it has received a $1 million Hoffman ALS Clinical Trial Award from The ALS Association to support the continued clinical development of MP-101, an investigational oral therapy being evaluated as a potential treatment for amyotrophic lateral sclerosis (ALS).
The funding is expected to help enable a planned 24-week clinical study in patients with sporadic ALS, building on encouraging findings from recent clinical research conducted in Europe. In those studies, participants with sporadic ALS who received MP-101 capsules demonstrated a rapid reduction in Neurofilament Light (NfL) levels, a biomarker commonly used to assess neuronal injury and disease activity.
The new award represents an important step in Mitochon Pharmaceuticals’ efforts to advance MP-101 into a Phase II clinical program. The company expects the planned study to begin in early 2027 and believes the research could provide additional insights into whether targeting mitochondrial dysfunction can influence disease progression in ALS.
Investigating Mitochondrial Dysfunction in ALS
ALS is a progressive neurodegenerative disorder characterized by the gradual loss of motor neurons, the nerve cells responsible for controlling voluntary muscle movement. As motor neurons deteriorate, patients can experience increasing muscle weakness, impaired movement, difficulty speaking and swallowing, and eventually respiratory complications.
Despite decades of research, ALS remains a challenging disease to treat, with a substantial unmet medical need for therapies capable of slowing the underlying neurodegenerative process. Researchers have increasingly investigated multiple biological mechanisms that may contribute to motor neuron damage, including mitochondrial dysfunction, oxidative stress, calcium toxicity, impaired energy production and cellular stress.
Mitochon Pharmaceuticals is developing MP-101 around the concept that mitochondrial dysfunction may represent an important therapeutic target in ALS. According to the company, the investigational therapy is designed to address several interconnected processes that can contribute to cellular injury.
MP-101 is described as a first-in-class, orally administered, brain-penetrating small molecule. Its proposed mechanism is centered on improving mitochondrial function by addressing elevated oxidative stress, calcium toxicity and insufficient cellular energy while also stimulating protective biological factors.
The company believes that this approach could help improve the resilience of motor neurons and potentially slow processes involved in their degeneration.
New Funding Supports Planned Phase II Study
The $1 million Hoffman ALS Clinical Trial Award is expected to provide financial support for the next stage of MP-101’s clinical development. The planned 24-week sporadic ALS study will build upon observations generated in earlier clinical investigations and is intended to further evaluate the potential effects of MP-101 in people living with ALS.
One of the findings that Mitochon Pharmaceuticals is highlighting is the observed decline in Neurofilament Light, or NfL, among sporadic ALS participants who received MP-101.
NfL is a structural protein found within neurons. When nerve cells are damaged, NfL can be released into surrounding fluids and subsequently detected as a biomarker of neuronal injury. Researchers have increasingly used NfL measurements in neurodegenerative disease studies to help monitor biological changes associated with neuronal damage.
A rapid reduction in NfL following treatment can therefore provide an important biological signal, although biomarker changes alone do not establish clinical efficacy. Further controlled clinical research will be necessary to determine whether reductions in NfL translate into meaningful benefits for patients, including preservation of motor function or slower disease progression.
The upcoming Phase II program is intended to provide additional data on MP-101’s safety, biological activity and potential therapeutic effects.
Focus on Calcium Toxicity and Motor Neuron Protection
Mitochon Pharmaceuticals’ development strategy is closely linked to research into the role of calcium toxicity in ALS. According to the company, research conducted by Dr. Lan Wei-LaPierre, PhD, of the University of Florida, helped support the scientific rationale behind investigating MP-101 in ALS.
The company says that this research aligns with its view that calcium toxicity may occur early in the process of motor neuron degeneration. Excessive calcium within cells can place significant stress on mitochondria and contribute to oxidative damage and impaired energy production.
Mitochondria are often described as the energy-producing components of cells, generating the energy required for essential cellular functions. Neurons, including motor neurons, have particularly high energy requirements because they must maintain long cellular structures and continuously support communication with other cells.
When mitochondrial function becomes impaired, cells may struggle to meet their energy requirements and can become increasingly vulnerable to oxidative stress and other forms of damage.
Mitochon Pharmaceuticals believes MP-101 may address these interconnected processes through what it describes as a targeted mitochondrial approach.
A “Mitochondrial Proton Therapy” Approach
The company characterizes MP-101’s mechanism as a form of “mitochondrial proton therapy.” Rather than functioning through a conventional receptor-targeting approach, the compound is designed around the biophysical properties of mitochondria and their role in maintaining cellular energy balance.
According to Mitochon Pharmaceuticals, MP-101 acts as a mitochondrial uncoupler. The company believes that carefully modulating mitochondrial function may help reduce excessive oxidative stress while improving cellular resilience.
The proposed approach is intended to restore aspects of mitochondrial health and bioenergetics while protecting neuronal cells from damage. This represents a different therapeutic strategy from treatments that primarily target symptoms or individual downstream pathways.
However, the ultimate clinical value of this mechanism will depend on results from well-controlled studies. The upcoming Phase II trial is therefore expected to be an important milestone in determining whether the biological rationale behind MP-101 can translate into measurable clinical benefits for people with ALS.
Leadership Highlights Importance of ALS Research
Mitochon Pharmaceuticals’ leadership emphasized the significance of the award and the company’s long-standing interest in ALS research.
Dr. John Geisler, PhD, Chief Scientific Officer and co-founder of Mitochon Pharmaceuticals, said ALS is an especially devastating disease because it often affects individuals during the most active periods of their lives. He noted that mitochondrial dysfunction has been a major focus of the company’s research and highlighted findings from Dr. Wei-LaPierre’s work supporting the relationship between MP-101’s pharmacology and the hypothesis that calcium toxicity may be an early contributor to motor neuron loss.
Robert Alonso, CEO of Mitochon Pharmaceuticals, described the $1 million award as an important endorsement of the company’s strategy of investigating mitochondrial uncoupling as a potential therapeutic approach for ALS. He said the funding will help support the Phase II study planned for early 2027.
The ALS Association also emphasized the importance of advancing promising therapeutic candidates through clinical development. Dr. Kuldip Dave, Chief Scientist at The ALS Association, said the organization is pleased to support the continued evaluation of MP-101 through its Hoffman ALS Clinical Trial Awards program.
The organization’s funding initiative is designed to support clinical programs at critical stages of development and help accelerate the search for treatments that could ultimately make ALS a more manageable and livable disease.
The $1 million award provides Mitochon Pharmaceuticals with additional resources as it prepares for the next stage of MP-101 development. The planned 24-week sporadic ALS study is expected to expand the clinical evidence generated to date and further investigate the compound’s potential effects on biomarkers and disease-related outcomes.
For the ALS community, the program reflects the continuing effort to explore new biological mechanisms beyond traditional therapeutic approaches. Mitochon’s Pharmaceuticals focus on mitochondrial health, oxidative stress, calcium toxicity and cellular energy production represents one such strategy.
While the early NfL findings provide a potentially encouraging biological signal, additional clinical evidence will be needed to determine whether MP-101 can deliver meaningful benefits to patients. Results from the planned Phase II study could therefore play an important role in shaping the future development of the therapy.
With support from The ALS Association and plans to initiate the next clinical stage in early 2027, Mitochon Pharmaceuticals is seeking to establish whether its mitochondrial-targeted approach can become a viable therapeutic option for people living with sporadic ALS.
About Mitochon Pharmaceuticals
Mitochon Pharmaceuticals was founded with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegenerative disorders, such as ALS, Huntington’s Disease (HD), Multiple Sclerosis (MS), Progressive Supranuclear Palsy (PSP), etc… Mitochon’s programs specifically harness the power of the mitochondria to provide broad neuroprotection. These compounds, through micro-dosing, elicit mild increases in energy expenditure that cascades into strengthening cellular survival. Additional Information: www.mitochonpharma.com
About ALS Association
The ALS Association is the largest ALS organization in the world. The ALS Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The mission of the ALS Association is to make ALS livable and cure it. For more information about the ALS Association, visit www.als.org.
About ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Few treatment options exist, resulting in a high unmet need for new therapies to address functional deficits and disease progression.